Comment on "The economics of follow-on drug research and development: Trends in entry rates and the timing of development"

被引：7

作者：

Hollis, A

机构：

[1] Univ Calgary, Dept Econ, Calgary, AB T2L 1B4, Canada

[2] Inst Hlth Econ, Calgary, AB T2L 1B4, Canada

来源：

PHARMACOECONOMICS | 2005年 / 23卷 / 12期

关键词：

D O I：

10.2165/00019053-200523120-00002

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：1187 / 1192

页数：6

共 21 条

[1] OLIGOPOLISTIC COMPETITION AND THE OPTIMAL PROVISION OF PRODUCTS [J].

ANDERSON, SP ;

DEPALMA, A ;

NESTEROV, Y .

ECONOMETRICA, 1995, 63 (06) :1281-1301

[2]

ANGELL M, 2000, TRUTH DRUG CO

[3]

[Anonymous], 2003, FRONT HLTH POLICY RE

[4]

Avorn J., 2004, POWERFUL MED

[5] Do pharmaceutical sales respond to scientific evidence? [J].

Azoulay, P .

JOURNAL OF ECONOMICS & MANAGEMENT STRATEGY, 2002, 11 (04) :551-594

[6]

COCKBURN IM, 1998, NBER WORKING PAPER, V6574

[7] The economics of follow-on drug research and development - Trends in entry rates and the timing of development [J].

DiMasi, JA ;

Paquette, C .

PHARMACOECONOMICS, 2004, 22 (Suppl 2) :1-14

[8]

DIMASI JA, COMMENT ME TOO DRUGS

[9]

DIXIT AK, 1977, AM ECON REV, V67, P297

[10] Pharmaceutical pricing in a regulated market [J].

Ekelund, M ;

Persson, B .

REVIEW OF ECONOMICS AND STATISTICS, 2003, 85 (02) :298-306

← 1 2 3 →